The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of ImmunityBio Inc (NASDAQ: IBRX) was $2.74 for the day, down -3.86% from the previous closing price of $2.85. In other words, the price has decreased by -$3.86 from its previous closing price. On the day, 3.91 million shares were traded. IBRX stock price reached its highest trading level at $2.87 during the session, while it also had its lowest trading level at $2.69.
Ratios:
Our analysis of IBRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.21 and its Current Ratio is at 3.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 06, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.
Piper Sandler Downgraded its Overweight to Neutral on May 12, 2023, whereas the target price for the stock was revised from $10 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2338430976 and an Enterprise Value of 2979409408. For the stock, the TTM Price-to-Sale (P/S) ratio is 158.65. Its current Enterprise Value per Revenue stands at 202.062 whereas that against EBITDA is -9.122.
Stock Price History:
The Beta on a monthly basis for IBRX is 0.41, which has changed by -0.49816847 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $10.53, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is -10.87%, while the 200-Day Moving Average is calculated to be -34.31%.
Shares Statistics:
IBRX traded an average of 6.02M shares per day over the past three months and 4436380 shares per day over the past ten days. A total of 852.74M shares are outstanding, with a floating share count of 88.78M. Insiders hold about 89.60% of the company’s shares, while institutions hold 9.90% stake in the company. Shares short for IBRX as of 1741910400 were 59544447 with a Short Ratio of 10.13, compared to 1739491200 on 56962454. Therefore, it implies a Short% of Shares Outstanding of 59544447 and a Short% of Float of 18.709999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of ImmunityBio Inc (IBRX) is currently drawing attention from 2 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.45 and -$0.58 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is -$0.34, with 2.0 analysts recommending between -$0.31 and -$0.36.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $19.74M to a low estimate of $13.78M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $40kFor the next quarter, 4 analysts are estimating revenue of $23.5M. There is a high estimate of $27.22M for the next quarter, whereas the lowest estimate is $19.64M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $121.8M, while the lowest revenue estimate was $85.38M, resulting in an average revenue estimate of $105.24M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $298.13M in the next fiscal year. The high estimate is $391M and the low estimate is $185.36M.
